跳至主要内容
临床试验/CTRI/2020/06/025999
CTRI/2020/06/025999尚未招募2 期

Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patients

BVG Life Sciences Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients admitted with RT-PCR confirmed COVID-19 illness.
  • Mild to Moderately Covid 19 disease (NEWS score less than or equal to 8)
  • Signed informed consent must be obtained and documented according to AYUSH GCP, and national/local regulations.

排除标准

  • Pregnant women
  • Breastfeeding women
  • Requiring ICU admission at screening
  • Patients above 65 years of age and below 18 Years
  • Past History of MI, Epileptic episodes
  • Any other co-morbidity (uncontrolled diabetes, severe hypertension from subject history) which is at critical stage at screening
  • Any other condition by which subject proves unfit from investigator perspective
  • Not giving consent.

研究者

发起方
BVG Life Sciences Ltd

相似试验